GREATER BIOCHEMICAL IMPROVEMENTS WITH HTD1801 (BERBERINE URSODEOXYCHOLATE) IN PATIENTS WITH PSC AND ELEVATED BASELINE ALKALINE PHOSPHATASE

被引：0
|
作者：
Forman, Lisa [1 ]
Kowdley, Kris V. [2 ]
Eksteen, Bertus [3 ]
Gunn, Nadege [4 ]
Sundaram, Vinay [5 ]
Landis, Charles [6 ]
Harrison, Stephen A. [4 ]
Levy, Cynthia [7 ]
Liberman, Alexander [8 ]
Di Bisceglie, Adrian M. [8 ]
Hirschfield, Gideon [9 ]
机构：
[1] Univ Colorado, Boulder, CO USA
[2] Liver Care Network, Seattle, WA USA
[3] Aspen Woods Clinic Inc, Denver, CO USA
[4] Pinnacle Clin Res, San Antonio, TX USA
[5] Cedars Sinai Med Ctr, Los Angeles, CA USA
[6] Univ Washington, Div Gastroenterol & Hepatol, Washington, DC USA
[7] Univ Miami, Schiff Ctr Liver Dis, Miami, FL USA
[8] Hightide Therapeut, Rockville, MD USA
[9] Univ Hlth Network, Toronto Gen Hosp, Toronto Ctr Liver Dis, Toronto, ON, Canada
来源：
HEPATOLOGY | 2022年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
4711
引用
收藏
页码：S1470 / S1472
页数：3
相关论文
共 18 条
  • [1] Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia
    Di Bisceglie, Adrian M.
    Watts, Gerald F.
    Lavin, Philip
    Yu, Meng
    Bai, Ru
    Liu, Liping
    LIPIDS IN HEALTH AND DISEASE, 2020, 19 (01)
  • [2] Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia
    Adrian M. Di Bisceglie
    Gerald F. Watts
    Philip Lavin
    Meng Yu
    Ru Bai
    Liping Liu
    Lipids in Health and Disease, 19
  • [3] Efficacy of berberine ursodeoxycholate (HTD1801) in Chinese and Western patients with type 2 diabetes
    Gan, S.
    Ji, L.
    Ma, J.
    Cheng, Z.
    Gunn, N. T.
    Neff, G. W.
    Liu, K.
    MacConell, L.
    DIABETOLOGIA, 2024, 67 : S341 - S341
  • [4] Berberine ursodeoxycholate (HTD1801) provides a unique therapeutic approach for patients with metabolic diseases and severe insulin resistance
    MacConell, L.
    Liberman, A.
    Flyer, A.
    Liu, K.
    DIABETOLOGIA, 2024, 67 : S339 - S339
  • [5] Berberine Ursodeoxycholate (HTD1801) provides a unique therapeutic approach for patients with metabolic diseases and severe insulin resistance
    MacConell, Leigh
    Liberman, Alexander
    Flyer, Abigail
    Liu, Kui
    JOURNAL OF HEPATOLOGY, 2024, 80 : S614 - S614
  • [6] EFFECTS OF HTD1801 (BERBERINE URSODEOXYCHOLATE) IN SUBJECTS WITH PRIMARY SCLEROSING CHOLANGITIS PREVIOUSLY EXPOSED TO UDCA
    Kowdley, Kris V.
    Forman, Lisa
    MacConell, Leigh
    Hirschfield, Gideon
    HEPATOLOGY, 2021, 74 : 760A - 761A
  • [7] PROOF OF CONCEPT STUDY OF HTD1801 (BERBERINE URSODEOXYCHOLATE) IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS NOT PREVIOUSLY EXPOSED TO UDCA
    Hirschfield, Gideon
    Forman, Lisa
    Eksteen, Bertus
    Gunn, Nadege T.
    Sundaram, Vinay
    Landis, Charles
    Harrison, Stephen A.
    Kohli, Anita
    Levy, Cynthia
    Di Bisceglie, Adrian M.
    Kowdley, Kris V.
    Floyd, Elson S.
    HEPATOLOGY, 2021, 74 : 73A - 73A
  • [8] TIME COURSE OF ONSET, INCIDENCE AND PREVALENCE OF GASTROINTESTINAL ADVERSE EVENTS WITH HTD1801 (BERBERINE URSODEOXYCHOLATE) IN PATIENTS WITH MASH AND T2DM
    Neff, Guy
    Harrison, Stephen
    Gunn, Nadege
    Flyer, Abigail
    Liu, Kui
    Liberman, Alexander
    HEPATOLOGY, 2024, 80
  • [9] Berberine Ursodeoxycholate (HTD1801) Improves Key Glycemic and Cardiometabolic Parameters across the Type 2 Diabetes Mellitus Disease Spectrum
    Ji, Linong
    Ma, Jianhua
    Ma, Yujin
    Cheng, Zhifeng
    Gan, Shenglian
    Yuan, Guoyue
    Liu, Dexue
    Li, Sheli
    Liu, Yu
    Xue, Xia
    Bai, Jie
    Wang, Kun
    Cai, Hanqing
    Li, Shu
    Liu, Kui
    Yu, Meng
    Liu, Liping
    DIABETES, 2024, 73
  • [10] EFFECTS OF HTD1801 (BERBERINE URSODEOXYCHOLATE) ON NON-INVASIVE FIBROSIS MARKERS IN SUBJECTS WITH PRESUMED NASH AND TYPE 2 DIABETES
    Harrison, Stephen A.
    Gunn, Nadege
    Neff, Guy W.
    MacConell, Leigh
    Loomba, Rohit
    HEPATOLOGY, 2021, 74 : 1136A - 1137A
12